Ob/Gyn Articles

Ob/Gyn

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Markman M et al. - Twelve cycles of single agent maintenance paclitaxel significantly improves PFS. Explanations for the lack of a favorable influence on overall survival include: (a) treatment at relapse equalized outcome; (b) the sample size was insufficient to reveal a difference; (c) “crossover” of patients from 3 cycles to longer treatment masked a potential difference. An ongoing phase 3 trial will hopefully provide a definitive answer to the question of the impact of this maintenance strategy on overall survival.

Related Articles

Preventing future cancers by testing women with ovarian cancer for brca mutations
Journal of Clinical Oncology, 10/22/09    Relevance Score: 72%

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09    Relevance Score: 70%

Unusual Metals Could Forge New Cancer Drug
ScienceDaily, 10/20/09    Relevance Score: 70%

New Drug Aims To Seek And Destroy Many Types Of Cancer
ScienceDaily, 10/07/09    Relevance Score: 70%

New drug aims to seek and destroy many types of cancer
EurekAlert, 10/06/09    Relevance Score: 70%

Today in Gynecologic Oncology...keeping you current

Cervical cytology in patients with postmenopausal bleeding
Diagnostic Cytopathology, 11/30/09

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review
Journal of Clinical Oncology, 11/30/09

Bevacizumab in the treatment of breast cancer
Cancer Treatment Reviews, 11/30/09